Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database

-Data to be Presented at the ESMO Sarcoma and Rare Cancers Annual Congress

-83% overall survival at two years vs. 34.3% OS from institutional database

-17.95 months median progression-free survival vs. 5.8 months PFS in historical group

CANbridge Pharmaceuticals Announces CAN008 Phase 1/2 Glioblastoma Multiforme Abstract Accepted by the ESMO Sarcoma and Rare Cancers Congress

CANbridge Named to South Reviews “2022 Annual List of Chinese Social Values”

Article from Cloud-based Medicine Studio | A national authoritative medical organization for rare diseases will be established, and the second list of rare diseases will be updated
(attachments: the first list and the national reimbursement drug list)

First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China

CANbridge Congratulates Apogenix on First Patient Dosed in Asunercept (CAN008) Phase 3 Trial for the Treatment of COVID-19

-CANbridge holds exclusive rights for the development of CAN008 for any indication in Greater China

-CAN008 currently in Phase 2 trial for the treatment of glioblastoma multiforme in China

CANbridge Consolidates Gene Therapy Portfolio

-Secures Exclusive Global Rights to Potentially Best-in-Class Spinal Muscular Atrophy Gene Therapy from UMass Chan Medical School

-Completes Technology Transfer of Two Gene Therapies for Lysomal Storage Diseases